Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,332

Participants

Timeline

Start Date

February 17, 2009

Primary Completion Date

July 23, 2009

Study Completion Date

October 15, 2009

Conditions
TetanusAcellular PertussisDiphtheriaDiphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
BIOLOGICAL

Boostrix®

Intramuscular, single dose.

BIOLOGICAL

Decavac™

Intramuscular, single dose.

Trial Locations (24)

21045

GSK Investigational Site, Columbia

21075

GSK Investigational Site, Elkridge

23185

GSK Investigational Site, Williamsburg

27262

GSK Investigational Site, High Point

28401

GSK Investigational Site, Wilmington

29464

GSK Investigational Site, Mt. Pleasant

30281

GSK Investigational Site, Stockbridge

32720

GSK Investigational Site, DeLand

33409

GSK Investigational Site, West Palm Beach

37620

GSK Investigational Site, Bristol

40509

GSK Investigational Site, Lexington

44122

GSK Investigational Site, Cleveland

44260

GSK Investigational Site, Mogadore

44281

GSK Investigational Site, Wadsworth

46254

GSK Investigational Site, Indianapolis

49127

GSK Investigational Site, Stevensville

67124

GSK Investigational Site, Pratt

70006

GSK Investigational Site, Metairie

76135

GSK Investigational Site, Fort Worth

84088

GSK Investigational Site, West Jordan

85741

GSK Investigational Site, Tucson

90057

GSK Investigational Site, Los Angeles

98801

GSK Investigational Site, Wenatchee

01757

GSK Investigational Site, Milford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY